ZVRA
ZEVRA THERAPEUTICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$10.45
+2.87%Year over year
Reported trailing growth
- Revenue
- +119.4%
- EBITDA
- +100.5%
- EBIT
- +132.8%
- EPS
- +1775.9%
- Free cash flow
- +170.1%
- Operating cash flow
- +172.3%
Forward estimates
Based on analyst estimates
- Revenue
- +26.4%
- EBITDA
- +13.0%
- EPS
- +2.3%
Three-year CAGR
- Revenue
- +118.8%
- EBITDA
- +229.2%
- EBIT
- +95.1%
- Net income
- +178.9%
- EPS
- +161.4%
- Free cash flow
- +96.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026